登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由郑州大学第一附属医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06647329,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
14 岁 至 75 岁;性别:不限
登记记录的入选字段
Less than 6 months since undergoing allogeneic hematopoietic stem cell transplantation.
排除标准第 9 条
Pregnant or breastfeeding women. Women of childbearing potential must have a negative serum pregnancy test within 48 hours prior to the start of lymphocyte-depleting chemotherapy.
排除标准第 14 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
入选标准第 6 条
Liver and kidney function, and cardiopulmonary function must meet the following requirements: a) Creatinine ≤ 1.5 × ULN; b) Left ventricular ejection fraction ≥ 50%; c) Blood oxygen saturation > 90%; d) Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN.
入选标准第 10 条
Active hepatitis (positive HBV DNA or HCV RNA testing).
排除标准第 6 条
Human Immunodeficiency Virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection.
排除标准第 7 条
History of deep vein thrombosis (DVT) (cancer-related thrombosis) or pulmonary embolism (PE) within 3 months prior to signing the informed consent form.
排除标准第 11 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06647329,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
The participant has given informed consent and signed the consent form, and is willing and capable of complying with the scheduled visits, study treatment, laboratory examinations, and other trial procedures. Clinically diagnosed as having relapsed/refractory malignant hematologic tumors: Anti-CD20 monoclonal antibodies Combination chemotherapy containing anthracyclines. Age 14-75 years (inclusive), both male and female. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Treatment-related antigen test results must be positive: Expected survival time greater than 3 months from the date of signing the informed consent form. HGB ≥ 70 g/L (transfusion allowed). Liver and kidney function, and cardiopulmonary function must meet the following requirements: a) Creatinine ≤ 1.5 × ULN; b) Left ventricular ejection fraction ≥ 50%; c) Blood oxygen saturation > 90%; d) Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN. Participants with a plan for pregnancy must agree to use contraception before enrollment and for six months after the study begins; if the participant becomes pregnant or suspects pregnancy, they must immediately notify the investigator.排除标准:Exclusion Criteria:
History of any of the following cardiovascular diseases within the past 6 months: New York Heart Association (NYHA) class III or IV heart failure, cardiovascular intervention (angioplasty or stenting), myocardial infarction, unstable angina, or other clinically significant heart diseases. History of severe pulmonary dysfunction. Concurrent advanced malignant tumors. Concurrent systemic fungal, bacterial, viral, or other infections that cannot be effectively controlled. Concurrent severe autoimmune diseases or congenital immunodeficiency. Active hepatitis (positive HBV DNA or HCV RNA testing). Human Immunodeficiency Virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection. History of severe allergic reactions to biologics (including antibiotics). Less than 6 months since undergoing allogeneic hematopoietic stem cell transplantation. Acute or chronic graft-versus-host disease (GvHD). History of deep vein thrombosis (DVT) (cancer-related thrombosis) or pulmonary embolism (PE) within 3 months prior to signing the informed consent form. Anticoagulation treatment for DVT or PE within 3 months prior to signing the informed consent form. History or clinical significance of CNS diseases at screening, such as epilepsy, seizure disorders, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or mental disorders. Pregnant or breastfeeding women. Women of childbearing potential must have a negative serum pregnancy test within 48 hours prior to the start of lymphocyte-depleting chemotherapy. Use of any of the following medications or treatments within the specified time before leukapheresis: Any factors judged by the investigator that may affect compliance with the study protocol, including uncontrollable medical, psychological, familial, sociological, or geographical factors, or unwillingness or inability to comply with the required procedures of the study protocol.
引自 ClinicalTrials.gov, NCT06647329, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06647329,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。